Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 268

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 268
---
 which may be (A) measured in absolute terms, as compared to any incremental increase, (B) measured in terms of
growth, (C) compared to another company or companies or the results of a peer group, (D) measured against the market as a whole, compared to applicable market indices and/or (E) measured on a pre-tax or post-tax basis.

Each executive officer who is selected to participate in the Bonus Plan will have a target bonus
opportunity set for each performance period. The bonus formulas will be adopted in each performance period by the board of directors or the compensation committee, as applicable, and communicated to each executive. The corporate performance goals
will be measured at the end of each performance period at such time as the board of directors or the compensation committee determines. If the corporate performance goals and individual performance objectives are met, payments will be made as soon
as practicable following the end of each performance period, but not later than 2.5 months after the end of the calendar year in which such performance period ends. Subject to the rights contained in any agreement between the executive officer and
us, an executive officer shall be required to be employed by us on the bonus payment date to be eligible to receive a bonus payment under the Bonus Plan. The Bonus Plan also permits the board of directors or the compensation committee to approve
additional bonuses to executive officers in its sole discretion.

193

DIRECTOR COMPENSATION The following table presents the compensation awarded to, earned by, or paid to each person who served as a non-employeemember of our board of directors during the fiscal year ended December 31, 2024 for their service on our board of directors during the year ended December 31, 2024. Non-employeedirectors Bruce Booth, Lucian Iancovici, H. Edward Fleming, Jr., Joshua Resnick, and Peter A. Thompson did not receive cash or equity compensation from us for their services as directors during 2024 due to their affiliation with Atlas Venture, TPG Growth, Enavate Sciences, RA Capital Management, L.P. and OrbiMed Advisors LLC, respectively. Our former non-employeedirector, Adam Rosenberg, also did not receive cash or equity compensation from us for his services as a director due to his former affiliation with RA Capital Management, L.P. and his former position as our chief executive officer prior to 2023. Other than as set forth in the table and described more fully below, we did not pay any